The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study by Ulf E. Kongsgaard et al.
ORIGINAL ARTICLE
The use of Instanyl® in the treatment of breakthrough
pain in cancer patients: a 3-month observational, prospective,
cohort study
Ulf E. Kongsgaard & Martin Eeg & Hanna Greisen
Received: 18 September 2013 /Accepted: 13 January 2014 /Published online: 8 February 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Purpose Instanyl® (intranasal fentanyl spray) is a novel treat-
ment for breakthrough pain (BTP) in cancer patients. It has
shown a rapid onset of pain relief in clinical trials. This study
examines the use of Instanyl® in real-life settings.
Methods A 3-month observational, prospective, cohort study
of cancer patients with BTP receiving Instanyl® (50, 100, or
200 μg) under routine clinical practice. Data were collected at
three time points corresponding with routine clinic visits –
baseline, Week 4, andWeek 13. Primary outcomes: success of
titration and maintenance dose after titration. Secondary out-
comes: change in maintenance dose of Instanyl® and level of
background pain medication; Brief Pain Inventory—Short
Form (BPI-SF) and Patient Treatment Satisfaction Scale
(PTSS) scores; adverse drug reactions (ADRs).
Results Titration with Instanyl® was successful in 84.5 % of
309 patients; most patients were titrated at the lowest dose
(50 μg). The majority showed no change inmaintenance dose,
with little change in the level of background pain medication.
BPI-SF and PTSS scores significantly improved from baseline
to Week 4. The main reason for terminating Instanyl® was
death, as expected due to the underlying disease; incidence of
ADRs was low and no fatal ADRs were reported.
Conclusions In a real-life group of cancer patients with dis-
ease progression, Instanyl® was titrated successfully at doses
<200 μg in the majority of patients, requiring only one dose,
with no further change in maintenance dose. Pain severity,
impact of pain on daily life, and treatment satisfaction signif-
icantly improved with Instanyl® treatment. No unexpected
ADRs occurred.
Keywords Cancer . Breakthrough pain . Fentanyl . Instanyl .
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Background
Cancer patients may experience persistent background pain,
interspersed with transitory exacerbations of pain that ‘break-
through’ the background medication, known as breakthrough
pain (BTP). BTP was first defined in 1990 as ‘a transitory
exacerbation of pain that occurs on a background of otherwise
stable pain in a patient receiving chronic opioid therapy’ [1].
Many definitions for BTP have since been proposed and are in
use but, as yet, no single definition has been widely accepted
[2]. The characteristics of individual BTP episodes vary [3–5];
there are reports of median times to reach peak intensity of 3
and 15 min, median durations of 30 and 60 min, and median
frequencies of 3 and 6 times per day [1, 6, 7]. BTCP episodes
are usually severe [1, 7].
BTP may impact on patients’ quality of life since it is
associated with impairments in daily physical functioning
and psychological distress [6, 8]. BTP places a high economic
burden on society and healthcare services [9, 10], and may be
a significant predictor of increased pain-related costs [11].
Successful management of BTP is an important unmet need
in the treatment of cancer patients.
Oral opioids (morphine, oxycodone, and hydromorphine)
are commonly used to treat BTP [12, 13], but can take
~30 min to produce an analgesic effect, which then lasts for
~4 h [12]. While this may be suitable for treating some pain
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conditions, the majority of BTP episodes require a treatment
with a fast onset of action and short duration of effect. To
improve the treatment of BTP, a range of fast-acting fentanyl
formulations have been developed and are approved in this
indication. These agents allow rapid absorption and quick
onset of effect, with good levels of acceptability to patients
[4]. For optimal BTP management, it is recommended that
opioids are titrated on an individual patient basis to a success-
ful dose that produces adequate analgesia, with minimal ad-
verse events [4, 14, 15].
Instanyl® (intranasal fentanyl spray [INFS]) is a novel
treatment option approved for the management of BTP in
adult cancer patients already receiving maintenance opioid
therapy for chronic cancer pain. Clinical studies in cancer
patients have shown that INFS provides clinically relevant
reductions in pain intensity [16], with superior efficacy and
patient preference, compared to oral transmucosal fentanyl
citrate (OTFC) [17]. Previous evaluations of Instanyl® were
conducted through controlled clinical trials. The aim of the
present study is to explore the actual use of Instanyl® and
success of titration in real-life settings, and evaluate the impact
of Instanyl® on patients’ daily life and treatment satisfaction.
Method
Study design
A non-interventional, 3-month observational, prospective, co-
hort study design was employed to follow cancer patients with
BTP receiving Instanyl® under routine clinical practice. The
study was conducted according to the Declaration of Helsinki,
Good Pharmacoepidemiological Practices, the Data Protec-
tion Directive, and any local requirements. Relevant Indepen-
dent Ethics Committees granted ethical approval.
Study participation had no impact on the patient (except for
the collection of informed consent, requested after the treat-
ment decision); the decision to prescribe Instanyl® was deter-
mined according to the summary of product characteristics
(SPC) before study entry and as part of current practice, and
Instanyl® was not taken until after the baseline visit. Patients
were not subjected to additional procedures; participating
study physicians were responsible for all decisions regarding
patient care.
Patients
Eligible patients were adult cancer patients (in-/outpatients)
suffering from BTP who had not been treated with Instanyl®
in the month prior to baseline, and who had been prescribed
Instanyl® in accordance with the SPC (i.e., at marketed doses
of 50, 100, or 200 μg) [18]. All patients provided informed
consent for the collection of data prior to study inclusion.
Data collection
Patients were recruited from 61 study centres across Denmark,
France, Greece, Ireland, Norway, Sweden and the UK. Data
were collected at three time points corresponding with pa-
tients’ usual scheduled visits (not pre-specified by the study
protocol)— baseline, Week 4 (−1 week/+2 weeks), andWeek
13 (−1 week/+4 weeks). For patients discontinuing before
Week 13, data were collected at the time of discontinuation.
Data were mainly obtained from source data, by the investi-
gator, and were collected for Instanyl®-treated patients only.
Two patient-rated questionnaires were validated for use in
the UK and France— the Brief Pain Inventory—Short Form
(BPI-SF) to assess severity of pain and impact of pain on daily
life domains, and the Patient Treatment Satisfaction Scale
(PTSS) to assess satisfaction with current pain medication.
Data from the questionnaires were collected only from those
countries in which this is allowed under the concept of a non-
interventional study (i.e., UK and France), and from sites
where these types of questionnaires are used in standard care.
BPI-SF and PTSS scores were assessed at baseline and Week
4 (not at Week 13, as the rapid progression of disease/low
completer rate expected in this patient population would likely
be a confounding factor by this time point).
Outcome variables
The primary outcome variables were, success of titration
(defined as reaching a maintenance dose) and dose level of
Instanyl® after titration (defined as the maintenance dose
reached).
Secondary outcome variables included, change in the
maintenance dose of Instanyl® and in the level of background
pain medication, BPI-SF and PTSS Total and domain scores,
adverse drug reactions (ADRs), and reason for, and time to,
Instanyl® termination.
Data analysis
Data from the overall analysis set (all patients enrolled in the
study, excluding those with data outside the permitted window
for visits) were analysed using epidemiological methods. Af-
ter the study ended, and before data analyses began, visit
windows were widened to include more data (a relatively high
proportion of visits occurred outside the originally planned
visit windows). The Week 4 visit window increased by 1 day
to −1 week/+2 weeks and 1 day; the Week 13 visit window
was revised to include any data collected fromDay 74 to study
end.
Planned recruitment was 300–1,000 patients, allowing the
proportion of successfully titrated patients to be estimated
within 3.1–5.7 % with 95 % confidence. An ADR that was
expected in one of 100 patients would be observed at least
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once in 300 to 1,000 patients dosed with Instanyl®, with a
probability of 0.95–0.99996.
Descriptive analyses were provided for all collected data.
For the primary outcome variables, the proportion of patients
with successful titration was calculated (with 95% confidence
intervals [CIs]) using the number of patients with a baseline
visit as the denominator; the proportions of patients titrated to
the different dose levels (50, 100, and 200 μg) were calculated
using the number of patients with successful titration as the
denominator. The primary outcome variable was examined
across levels of baseline characteristics – age, gender, body
mass index (BMI), type of cancer (including presence and site
of metastases), BTP episodes by frequency, duration and
localisation, current BTP medication, and current background
pain medication — multivariate logistic regression adjusted
for potential confounders of any associations.
For the secondary efficacy variables, the change in main-
tenance dose from Week 4 to Week 13 was analysed for
patients reaching a maintenance dose. Since a patient’s pain
could change, the protocol allowed for a dose adjustment
(increase or decrease) after the first maintenance dose was
achieved at the end of titration. Therefore, the highest pre-
scribed dose level and the usual dose per BTP episode were
Table 1 Patient demographics and baseline characteristics (overall anal-
ysis set, N=309)
Mean age, years (SD) 60 (12.8)
Male, n (%) 173 (56)
Mean BMI, kg/m2 (SD) 23.5 (4.3)
Site of primary tumour, n (%)
Lung/respiratory system 78 (25.2)
Colon/rectal system 41 (13.3)
Breast 32 (10.4)
Gastro-oesophageal system 19 (6.1)
Head and neck 18 (5.8)
Prostate 18 (5.8)
Pancreas 17 (5.5)
Female genital 16 (5.2)
Urological 16 (5.2)
Unknown primary tumour 14 (4.5)
Haematological 12 (3.9)
Musculoskeletal system 6 (1.9)
Central nervous system 1 (0.3)
Liver 0 (0.0)
Other 21 (6.8)
Metastases present, n (%)
Overall 263 (85.1)
In bone 162 (52.4)
In areas other than bonea 214a (69.3)





Usual duration of BTP episodes, n (%)
<30 min 87 (28.2)
30–60 min 154 (49.8)
>60 min 60 (19.4)
<1 hb 6 (1.9)
Not recorded 2 (0.6)
Localisation of BTP, n (%)
At site of primary tumour 121 (39.2)
At site of metastases 215 (69.6)
Other 37 (12.0)
Patients reported to be receiving treatment for BTP, n (%) 192 (62.1)
Current BTP treatment, n (%)
Fentanylc 18 (5.8)
Morphined 75 (24.3)
PCA pump 1 (0.3)
Oxycodone/oxycodone hydrochloride 93 (30.1)
Ketobemidone/ketobemidone hydrochloride 10 (3.2)
Other 15 (4.9)
None 117 (37.9)
Patients receiving background medication, n (%) 309 (100.0)








Weak opioid 23 (7.4)
Non-opioid 12 (3.9)
Adjuvant drug 11 (3.6)
Other treatment 1 (0.3)








Weak opioid 23 (14.3)
N number of patients, n number of patients with event, SD standard
deviation, BMI body mass index, BTP breakthrough pain, PCA patient-
controlled analgesia
a Of these, 113 patients also had metastases present in bone
b Category was used prior to a protocol amendment. However, it can be
seen that 247 (79.9 %) patients were experiencing BTP with a usual
duration of 60 min or less
c Includes oral transmucosal fentanyl citrate, n=5 (1.6 %); fentanyl buccal
tablet, n=3 (1.0 %); sublingual fentanyl, n=10 (3.2 %)
d Includes oral morphine, n=53 (17.2 %) and other forms of morphine,
n=22 (7.1 %)
e Some patients were taking ≥1 type of medication for background pain
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also recorded. The change in the level of background pain
medication (expressed as morphine equivalents) was analysed
from baseline to Week 4 and to Week 13, and fromWeek 4 to
Week 13. BPI-SF and PTSS Total and domain scores (for UK
and France) were summarised at baseline and Week 4; the
change from baseline toWeek 4 was analysed using a paired t-
test or a non-parametric Wilcoxon signed-rank test, where
appropriate. Incidence rates of ADRs were summarised, as
were the primary reasons for terminating Instanyl® treatment.
Time to discontinuation of Instanyl® was calculated as the
difference in days between baseline and the last known date of
Instanyl® treatment, plus 1 day, and presented as a Kaplan–
Meier plot (with 95 % CI).
For descriptive statistics, no imputation of missing data
occurred. Patients lacking data to show whether or not a
successful titration had been achieved were considered not
to have been successfully titrated. Questionnaire data were
treated as missing and excluded from the analyses where
patients had not completed total and domain scores for all
four pain severity questions and a minimum of four interfer-
ence questions on the BPI-SF, and if fewer than four of the six
questions of the PTSS had been completed.
Results
The study was initiated on 28 December 2009 and completed
on 19 April 2012. In total, 309 patients were enrolled, com-
prising the overall analysis set; 107 (34.6 %) patients com-
pleted the study. Data was collected at baseline for all patients,
and within the Week 4 and Week 13 windows for 225
(72.8 %) and 128 (41.1 %) patients, respectively.
Patient demographics and baseline characteristics are
summarised in Table 1. The most common site of primary
tumour was the lung/respiratory system and the majority of
patients had metastases. Most patients were experiencing 3–4
episodes of BTP per day, with approximately one quarter of
patients suffering from >4 BTP episodes daily. In the majority
of patients, BTP episodes lasted 30–60 min, and originated
from the site of metastases. At baseline, 117 (37.9 %) patients
were not receiving any BTP treatment. Oral oxycodone or oral
morphine was the sole BTP treatment for 80 (26 %) and 46
(15 %) patients, respectively. Fentanyl was most commonly
prescribed to treat background pain, followed by oxycodone.
Success of titration
Excluding Ireland, where only two patients were enrolled, the
proportion of patients successfully titrated to a maintenance
dose was greatest in Greece and lowest in the UK (Fig. 1). For
all countries combined, the majority of patients were success-
fully titrated to a maintenance dose of 50 μg, with fewest
patients titrated to 200 μg. A total of 48 (15.5 %) patients were
not successfully titrated due to patients being withdrawn from
(n=46), or not completing (n=2), the study.
Greater success of titration was associated with being
younger, female, having a higher BMI, and having metastases
(Table 2). The logistic regression showed that, after account-
ing for country differences, a higher success rate was associ-
ated with being female (odds ratio [OR]=3.6; 95 % CI: 1.6,
7.8), having BTP originating from the site of the primary
tumour (OR=3.1; 95 % CI: 1.3, 7.4), and the presence of
bone metastases (OR=2.2; 95 % CI: 1.0–4.9). However, the
overall success rate was not affected when adjusting for these
variables.
Maintenance treatment
The median time from baseline to maintenance treatment was
29 days (95 % CI: 29–31), possibly a reflection of the study
Fig. 1 Success of titration—
proportion of patients
successfully titrated to a
maintenance dose of Instanyl®
(50, 100 or 200 μg) across seven
European countries. Doses
represent the first maintenance
dose level of Instanyl® achieved
at the end of titration
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design (i.e., investigators first determined the maintenance dose
atWeek 4). The most common first maintenance dose achieved
was 50 μg, followed by 100 μg, then 200 μg; a similar pattern
was observed for the highest prescribed dose level achieved
(Table 3). The usual dose per BTP episode was 50 or 100 μg in
themajority of patients (Table 3).Most patients (70%) received
one dose per BTP episode (50μg: 70%; 100μg: 73%; 200μg:
64 %). The majority showed no change in maintenance dose
from Week 4 to Week 13 (Table 4).
Background medication
There was little evidence of a change in background pain
medication (as morphine equivalent) from baseline to Week
4 (median change=0 mg/day; inter-quartile range, Q1–Q3: 0–
60) or from Week 4 to Week 13 (median change=0 mg/day;
Q1–Q3: 0–77), but a slight increase from baseline to Week 13
(median change=40mg/day; Q1–Q3: 0–120). No relationship
between the successfully titrated dose of Instanyl® and level
of background medication was found.
Duration of Instanyl® treatment
AtWeek 4, 172 (55.7 %) patients were treated with Instanyl®,
falling to 103 (33.3 %) patients at Week 13. The median
duration of Instanyl® treatment (baseline to end of treatment)
was 50 days. The majority of treatment terminations were due
to the patients having died (n=72; 23.3 %), which was ex-
pected given the underlying disease (no deaths were reported
as fatal ADRs). For patients who had not died, the main
reasons for termination were lack of efficacy (n=47;
15.2 %), and ‘other’ reasons (n=46; 14.9 %; including six
(1.9 %) patients who reported having no more BTP). Of those
patients terminating due to lack of efficacy, 14 (4.5 %) were
titrated to 50 μg, seven (2.3 %) were titrated to 100 μg, and
four (1.3 %) were titrated to 200 μg; the remaining 22 (7.1 %)
patients terminated before a successful titration. An inability
to administer drug accounted for Instanyl® termination in 20
(6.5 %) patients, with the fewest terminations reported in
patients with an ADR (n=7; 2.3 %).
Pain and treatment satisfaction
There was a significant reduction in BPI-SF Total score, and in
the domain scores for severity of pain and interference with
daily activities, from baseline toWeek 4; worst pain scores also
significantly improved (Table 5). There was a significant in-
crease in PTSS total score from baseline to Week 4 (Table 5).
Adverse drug reactions
ADRs were extracted from the international drug safety data-
base using the cut-off date of 26 April 2012. By this time, a
Table 2 Success of titration by patient demographics and baseline char-














<18.5 (underweight) 21/27 (77.8)
18.5 to <25 (normal weight) 147/174 (84.5)









In areas other than bone
Yes 182a/214 (85.0)
No 79/95 (83.2)





Usual duration of BTP episodes
<30 min 76/87 (87.4)
30–60 min 133/154 (86.4)
>60 min 48/60 (80.0)
<1 hb 4/6 (66.7)
vNot recorded 0/2 (0.0)
Localisation of BTP
From site of primary tumour 107/121 (88.4)
From site of metastases 183/215 (85.1)
Other 30/37 (81.1)
Currently treated for BTP
Yes 158/192 (82.3)
No 103/117 (88.0)
Data are presented as n (%)
N number of patients, n number of patients with event, BMI body mass
index, BTP breakthrough pain.
a Of these, 113 patients also had metastases present in bone
b Category was used prior to a protocol amendment. However, it can be
seen that 213 (68.9 %) patients were experiencing BTP with a usual
duration of 60 min or less
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total of 18 ADRs had been reported for nine (2.9 %) patients.
Of these, three (1.0 %) patients reported serious ADRs. ADRs
were considered to be related to Instanyl® for seven (2.3 %)
patients (six [1.9 %] patients with non-serious ADRs; one
[0.3 %] patient with serious ADRs). No fatal ADRs were
reported. All patients recovered from their ADRs; all, but
one, patient discontinued the study early.
Discussion
Despite various fast-acting fentanyl formulations being avail-
able for the treatment of BTP, evidence suggests that their use
is not widely recognised [7, 19]. For example, a recent Euro-
pean survey reports that 38.4 % of oncology nurses are un-
aware that medications specific for BTP exist; 57% stated that
oral morphine was normally prescribed for BTP [13].
The present study aimed to evaluate the actual use of
Instanyl® and success of titration in real-life settings during
the early post-launch phase in participating countries, outside
the restrictions of a clinical trial. The low number of patients
recruited in the study may partly be due to Instanyl® being
used in a more carefully selected patient population during
this period (i.e., patients with problematic BTP that could not
be sufficiently addressed by previously available treatment
options, and/or those more positive to new treatments).
The study recruited a patient population with a high pres-
ence of metastases all receiving medication for background
pain. Most patients were experiencing multiple daily episodes
of BTP and were receiving treatment for BTP at baseline. The
observation that some patients were experiencing fewer than
one, or more than four, BTP episodes daily highlights the need
for a treatment strategy tailored to the individual patient. Data
collected also indicated that some patients were receiving
conventional oral opioids (morphine or oxycodone) alone
for BTP, suggesting less than optimal pain management. The
high number of patients who died during the study reflected
the disease severity; indeed, this was the main reason reported
for Instanyl® treatment termination. Lack of efficacy was
cited as the main reason for terminating Instanyl® among
patients who had not died, possibly because these patients
were not titrated to the highest dose. However, this is merely
speculation, since the exact reasons cannot be determined.
Overall, successful titration was high in this study (84.5%).
Although a direct comparison to existing data from clinical
trials cannot be made, success rates of approximately 70 %
have been reported for fast-acting fentanyl formulations
[20–22]. The differences in success of titration based on
Table 3 Dose level of Instanyl® after successful titration
Number of patients successfully titrated (%)
50 μg 100 μg 200 μg 150–200 μg >200 μg
First maintenance dose level achieved 130 (49.8) 95 (36.4) 36 (13.8) – –
Highest prescribed dose level achieved 119 (45.6) 97 (37.2) 44 (16.9) – –
Usual dose per BTP episodea 82 (31.4) 103 (39.5) – 55 (21.1) 19 (7.3)
Data based on the total number of patients who were successfully titrated (N=261)
N number of patients, BTP breakthrough pain
a Reflects the total dose taken per episode (i.e., the prescribed dose x the number of times the dose was taken, e.g., 50 μg taken three times gives a usual
dose of 150 μg)
Table 4 Change in Instanyl® maintenance dose strength
Week 13 Total
50 μg 100 μg 200 μg
Week 4 50 μg 32 (30.5) 15 (14.3) 6 (5.7) 53 (50.5)
100 μg 4 (3.8) 23 (21.9) 11 (10.5) 38 (36.2)
200 μg 2 (1.9) 0 (0.0) 12 (11.4) 14 (13.3)
Total 38 (36.2) 38 (36.2) 29 (27.6) 105 (100.0)
Data presented as n (%), based on the total number of patients with data at
Week 4 and Week 13 (N=105)
N number of patients, n number of patients with event










BPI-SF total score −1.0 (2.1) <0.001 −10.2 (57.9) <0.001
Severity of pain −0.8 (2.0) <0.001 −10.6 (45.6) 0.009
Interference with
daily activities
−1.1 (2.5) <0.001 −3.8 (103.6) <0.001
Worst pain score −1.2 (2.6) <0.001 −12.8 (42.7) <0.001
PTSS Total score 14.4 (20.9) <0.001 36.8 (57.9) <0.001
Data presented are mean (SD), based on questionnaires administered to
patients in the UK and France: BPI-SF, N=126; PTSS, N=37
BPI-SF Brief Pain Inventory—Short Form, PTSS Patient Treatment Sat-
isfaction Scale, SD standard deviation,UKUnited Kingdom,Nnumber of
patients
1660 Support Care Cancer (2014) 22:1655–1662
patient characteristics were minor and considered of less im-
portance for clinical practice. Successful titration was highest
in Greece and Norway (>90 %), and lowest in the UK and
France (<75). It is difficult to explain the observed differences
between countries, and the reasons provided here are merely
speculative. For example, the high success rate seen in Nor-
way may be due to the high proportion of patients titrated to
200 μg. However, this theory does not support the high
success rate observed in Greece, where the majority of pa-
tients were successfully titrated to 50μg. Evaluation of patient
characteristics did not offer any further potential explanations
for the inter-country differences observed. Indeed, success
rates may be influenced by more factors than were measured
in this study.
Of the patients who were successfully titrated, the majority
achieved this with the lowest dose of Instanyl® (50 μg),
possibly reflecting the high bioavailability observed for intra-
nasal fentanyl [23], and supporting titration from the lowest
dose. The observation that most patients achieved successful
titration with only one dose of Instanyl® has positive impli-
cations for BTP management.
Given the disease characteristics of the patients recruited,
disease progression may have been expected, which would
have required an increase in the Instanyl® dose. In fact, the
majority of patients showed no change in the maintenance
strength dose throughout the study, indicating the effective-
ness of Instanyl® in treating BTP. A lack of relationship
between the maintenance dose achieved and the level of
background pain medication is consistent with other trials
involving Instanyl® (unpublished data) and OTFC [24].
Assessments of pain and its impact on daily life showed
reductions in pain severity (11 %), interference with daily
activities (4 %), and worst pain score (13 %) with Instanyl®
that are considered to be highly clinically relevant in a popu-
lation of patients for whom pain intensity would be expected
to increase. Patients’ satisfaction with treatment increased
during the treatment period. These results indicate the effec-
tiveness of Instanyl® in a patient population with a high
probability of disease progression.
As with any study, there are limitations to consider. Firstly,
in some countries, patient numbers were small. Secondly, the
low number of ADRs reported suggests that patients in such a
population (i.e., terminally ill cancer patients receiving treat-
ment for their pain) do not report adverse events due to the
disease severity. Indeed, the common side effects of fentanyl
can be confused with the side effects arising from a patient’s
background opioid medication. Thirdly, the lack of a compar-
ator arm may be seen as a further limitation. However, includ-
ing a comparator arm (placebo or other reference drug) would
not have contributed to the main objective of describing the
real-life use of Instanyl® for treating BTP in cancer patients.
Another limiting factor is that although the overall amount of
pain medication was determined before and after initiation of
Instanyl® treatment, as there was no placebo control the effect
of Instanyl® could not be differentiated from that of existing
treatment. Oral morphine and other pain medications are used
to treat both background pain and BTP, and these effects
cannot be separated. Furthermore, the need for pain treatment
in the individual patient may change during the study. Finally,
although not a limitation per se, it is a common observation of
many studies that simply being enrolled into a trial can influ-
ence a patient’s perception of treatment satisfaction [25].
In conclusion, the study has shown that in a real-life group
of patients with disease progression, the majority achieved a
successful titration with Instanyl® at doses below 200 μg;
over one-third of patients were successfully treated with the
lowest dose of 50 μg. The majority of patients were success-
fully titrated with one dose of Instanyl® and required no
further change to their maintenance dose. The severity of pain
and associated impact on daily life significantly improved
with Instanyl® treatment, as did the level of patient satisfac-
tionwith treatment. No unexpected adverse reactions occurred
with Instanyl® treatment.
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